Virbac downwind

The French veterinary laboratory Virbac records good 2010 results (T/O €57 millions ($800 million) + 10.8%) and hopes for a further robust internal growth (+ 5 to + 7%) in 2011.

External growth is not forgotten; Virbac acquired a small unit in Colombia, the Fort Dodge products portfolio in Australia, studies two co-enterprises in China and would like to benefit of the regulatory disinvestments required by the Sanofi Aventis / Merck ScheringPlough merger, and particularly the US vaccines operation. In the pet industry, Virbac develops in the USA Efipro, an answer to Merial's blockbuster Frontline. With all that on his plate, whether Mr Jean Pierre Dick would find time to race the oceans is an additional question.